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Cognitive impairment is a significant risk factor for hazardous driving among older drivers
with Alzheimer’s dementia, but little is known about how the driving behavior of mildly
symptomatic compares with those in the preclinical, asymptomatic phase of Alzheimer’s
disease (AD). This study utilized two in-car technologies to characterize driving behavior
in symptomatic and preclinical AD. The goals of this pilot study were to (1) describe
unsafe driving behaviors in individuals with symptomatic early AD using G-force triggered
video capture and (2) compare the driving habits of these symptomatic AD drivers
to two groups of cognitively normal drivers, those with and those without evidence
of cerebral amyloidosis (CN/A+ and CN/A−) using a global positioning system (GPS)
datalogger. Thirty-three drivers (aged 60+ years) were studied over 3 months. G-force
triggered video events captured instances of near-misses/collisions, traffic violations,
risky driver conduct, and driving fundamentals. GPS data were sampled every 30 s and
all instances of speeding, hard braking, and sudden acceleration were recorded. For the
early AD participants, video capture identified driving unbelted, late response, driving
too fast for conditions, traffic violations, poor judgment, and not scanning intersections
as the most frequently occurring safety errors. When evaluating driving using the GPS
datalogger, hard breaking events occurred most frequently on a per trip basis across all
three groups. The CN/A+ group had the lowest event rate across all three event types
with lower instances of speeding. Slower psychomotor speed (Trail Making Part A) was
associated with fewer speeding events, more hard acceleration events, and more overall
events. GPS tracked instances of speeding were correlated with total number of videocaptured near-collisions/collisions and driving fundamentals. Results demonstrate the
utility of electronic monitoring to identify potentially unsafe driving events in symptomatic
and preclinical AD. Results suggest that drivers with preclinical AD may compensate for
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early, subtle cognitive changes by driving more slowly and cautiously than healthy older
drivers or those with cognitive impairment. Self-regulatory changes in driving behavior
appear to occur in the preclinical phase of AD, but safety concerns may not arise until
symptoms of cognitive impairment emerge and the ability to self-monitor declines.
Keywords: driving, Alzheimer’s disease, naturalistic, technology, preclinical Alzheimer’s disease, driving mobility

INTRODUCTION

with any aggressive behaviors and showed a greater decline across
a 2.5-year follow-up period in the number of days driving per
month and number of trips taken (Roe et al., 2019).

Older drivers with cognitive impairment are at high risk
for unsafe driving, carrying a relative crash risk of 2–5
times higher compared to matched controls (Marshall, 2008).
Alzheimer’s disease (AD), one of the most prevalent diseases
affecting cognition in older adults (Alzheimer’s Association,
2019), adversely impacts driving. Individuals with AD are at
increased risk for failing a road test with disease progression
(Duchek et al., 2003; Ott et al., 2008), make more safety errors
when driving in their own environment compared to cognitively
normal older adults (Davis et al., 2012), and are at greater
risk for crashes (Drachman and Swearer, 1993). Despite their
increased risk, drivers with AD continue to drive during their
disease course but may modify their behavior by reducing
driving in complex situations (Festa et al., 2013; Molnar et al.,
2013). This includes driving without passengers, during daytime
hours, good weather, light traffic, and residential rather than
commercial environments. Festa et al. (2013) Despite behavioral
modification, however, most drivers with AD eventually need to
cease driving due to progressive cognitive and functional decline
(Connors et al., 2018).
Little is known about how driving is affected early in the
disease process or the pathological process underlying that
decline. AD begins decades (∼2–3) before overt expression of
cognitive symptoms as beta amyloid, the pathological marker of
AD, begins to accumulate in the brain. The presence of cerebral
amyloid has been directly associated with driving. Specifically,
several postmortem studies of the brains of older drivers who
were killed in motor vehicle crash (MVCs) have found that many
had the neuropathologic changes of AD but had never been
diagnosed (Johansson et al., 1997; Viitanen et al., 1998; Kibayashi
and Shojo, 2002; Gorrie et al., 2007).
The development of biomarkers for AD has allowed for
in vivo studies of amyloid deposition and driving behavior.
Traffic violations and accidents over the 3 years prior to
brain imaging was strongly related to accumulating amyloid on
positron emission tomography [PET] scans, even in individuals
not yet displaying measurable cognitive impairments resulting
from the disease (i.e., preclinical AD) (Ott et al., 2017b). More
abnormal levels of cerebral amyloid detected using Pittsburgh
compound B radiotracer via PET predicted poorer performance
on a standardized road test among cognitively normal older
adults (Roe et al., 2017). Using naturalistic methodology, real
world driving behavior appears to change even in the preclinical
phase of the disease with amyloid positive older adults driving
to fewer places/unique destinations, traveling fewer days, and
taking fewer trips compared to amyloid negative same-aged
peers. Furthermore, those with preclinical AD had fewer trips
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CURRENT STUDY
To date, there is little data examining the spectrum of age-related
driving behavior ranging from normal cognition to preclinical
AD to symptomatic AD. Using a convenience sample of older
drivers, the goal of this pilot study was to describe naturalistic
driving behavior among these three groups using in-vehicle video
and global positioning system (GPS) technologies. The first aim
was to describe the types of hazardous driving errors captured by
video technology in a subset of the sample of older adult drivers
with early AD. The second aim was to compare the driving
behaviors of drivers with early AD to two groups of cognitively
normal (CN) drivers, those with evidence of brain amyloid
(preclinical AD; CN/A+) to healthy adults without evidence of
brain (CN/A−) over 3 months of naturalistic driving.

MATERIALS AND METHODS
Participants
Symptomatic AD drivers (n = 11) were recruited from a
multidisciplinary outpatient memory clinic in Rhode Island. All
participants underwent a diagnostic evaluation by a neurologist
at the Center. Neurological examination results were judged to be
normal for age or consistent with AD. For inclusion, Mini-Mental
State Examination (MMSE) (Folstein et al., 1975) scores were
<28 and Clinical Dementia Rating (Morris, 1993) (CDR) scores
were categorized as CDR = 0.5 or 1, indicating questionable or
mild dementia. It is well established that CDR 0.5 is equivalent
to mild cognitive impairment (Morris et al., 2001). Participants
met diagnostic criteria for possible or probable AD based on
NINCDS-ADRDA criteria (McKhann et al., 1984). Patients were
on a stable dose of a cholinesterase inhibitor for 6 weeks, if
prescribed. The amyloid status was known only for a subset of
the cognitively impaired participants, as amyloid imaging was not
a standard part of the original study protocol. Amyloid imaging
was obtained within 18 months of study entry (M = 333 days;
range = 56–511 days). Amyloid imaging results are presented
in Table 1 to add to the clinical characterization of the early
AD group. This subset of participants underwent amyloid PET
imaging using the radiotracer 18 F-Florbetapir (Clark et al., 2011)
as part of their participation in other clinical research studies. An
established standardized uptake value ratio (SUVR) threshold of
>1.19 was used to indicate amyloid PET positivity (Clark et al.,
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TABLE 1 | Demographic characteristics of participants.
CDR 0 (CN/A−) (n = 11)
(%) or M (SD)

CDR 0 (CN/A+) (n = 11) N
(%) or M (SD)

CDR.5/1 (AD) (n = 11) N
(%) or M (SD)

Women, N

5 (45%)

5 (45%)

5 (45%)

White, N

10 (91%)

11 (100%)

11 (100%)

MCI/CDR.5, N

Statistic

p

0 (0%)

0 (0%)

9 (82%)

MMSE (total)

29.18 (1.67)

29.09 (1.30)

25.18 (3.84)

F = 9.66

0.001*

Age, years

73.33 (5.21)

73.71 (5.12)

72.88 (6.84)

F = 0.56

0.95

Education (years)

17.45 (1.97)

16.55 (1.86)

15.45 (3.36)

F = 1.78

0.19

*Implies difference between CDR 0 vs. CDR.5/1.CN/A−, cognitively normal/amyloid negative; CN/A+, cognitively normal/amyloid positive; AD, Alzheimer’s disease; CDR,
Clinical Dementia Rating Scale; MCI, mild cognitive impairment.

ApoE ε4 allele carriers, and 63.6% were ApoE ε4 allele carriers
in the amyloid positive group. The participant’s vehicle had to
be manufactured in the year 1996 or newer in order to have
access to the onboard diagnostic port (OBDII). Study protocols
were approved by the Washington University Human Research
Protection Office, and written informed consent was obtained
from all participants.

2012; Johnson et al., 2013). All scans were read by two clinical
neuroradiologists who gave also gave a clinical read of the scan.
One participant had a SUVR threshold of 1.16 but had a positive
clinical read. That participant was considered to be amyloid
positive in this study. The sample was further characterized by
apolipoprotein (ApoE) genotype, a known risk factor for AD
if the ε4 allele is present. Of the eight participants with ApoE
genotyping completed, 50% possessed the ε4 allele.
All participants were >60 years of age, English speaking
with a valid driver’s license. Exclusion criteria included
ophthalmologic, physical, or neurologic disorders other than
dementia that impair their driving abilities, visual acuity worse
than 20/40 in best eye using distance vision measured by
wall chart, homonymous hemianopia or bitemporal hemianopia,
musculoskeletal disorders causing major physical handicaps,
history of alcohol or substance abuse by DSM V criteria within
the past year, had used sedating medications that impair level
of consciousness or attention, had a language impairment that
would interfere with the ability to participate in the study, or
had a previous road test evaluation or opinion of caregiver or
health professional that they were unsafe to drive. Study protocols
were approved by the Rhode Island Hospital Institutional Review
Board, and all participants provided written informed consent
that was also signed by a study partner.
Since beta-amyloid is the primary driver and earliest marker
of AD pathogenesis and cascade, it was selected as the main
biomarker (Jack et al., 2018). A group of cognitively normal
drivers were selected from participants enrolled in a longitudinal
study assessing preclinical AD and driving performance (R01
AG043434) at Washington University School of Medicine in St.
Louis and matched for age and gender to the early AD group.
All participants were cognitively normal (CDR = 0), ≥65 years
old, had a valid driver’s license, drove at least once per week,
and had in vivo imaging of amyloid using PET with either
Pittsburgh compound B (PIB) or florbetapir AV45 radiotracer
to confirm group membership. PET imaging was selected if it
occurred 2 years before or 6 months after the installation date of
datalogger in the participant’s vehicle. Eleven participants were
selected with amyloid negative scans and 11 with evidence of
amyloid based on centiloid values (Su et al., 2015). Accepted cutoffs of centiloids were based on the mean cortical SUVR with
partial volume correction via regional spread function (RSF) [PIB
MCSUVR RSF ≥ 16.4 and AV45 MCSUVR RSF ≥ 20.6] (Su et al.,
2015, 2018, 2019). The amyloid negative group had 27.3% the
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Study Procedures
Cognition
At study enrollment, all participants completed cognitive
measures, including a global measure of cognition (MMSE) and
a task of psychomotor speed and set shifting (Trail Making Parts
A and B, respectively) (Reitan, 1956). Trail making was selected
because it has been shown to be related to naturalistic driving
errors (Papandonatos et al., 2015). Time in seconds to complete
the tasks were used in data analyses. Higher scores on Trails A
and B reflect worse performance (i.e., slower time).

Technology
Vehicles were equipped with two forms of technology, an eventbased video recording system (Drivecam) was equipped for
CDR > 0 drivers and a GPS datalogger was equipped for all
drivers. Because these results reflect the combination of drivers
from two different parent studies, only the vehicles of the mild
AD group were equipped with the camera system. All three
groups had the GPS datalogger installed to capture naturalistic
driving behavior.
The DriveCam video camera is a palm-sized, exception-based
video event recorder that was mounted in a bracket secured
to the windshield behind the rearview mirror with an adhesive
similar to what holds the rearview mirror in place. This system
is a validated method for detecting and evaluating driving safety
errors in AD (Ott et al., 2017a). Camera views were the forward
roadway and the driver in the vehicle interior. Once installed, the
camera continuously captured video and temporarily saved the
previous several seconds in a video buffer. If the device was not
triggered by excessive g-forces, all data was deleted permanently
10 s later. Data were protected from unauthorized access and
removal and was only viewable by DriveCam’s staff and site
research staff. The site research staff, comprised of a neurologist,
neuropsychologist, and occupational therapist specializing in
driving evaluation, reviewed the events weekly to ensure no
egregious events occurred that would prompt recommendation
R
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points were used to examine correlational relationships between
driving events captured with video and GPS logger behavior.
Driving behavior captured by the DRIVES were aggregated
from daily trip reports for each vehicle over the course of the
participant’s entire participation in the study (up to 5 years).
Daily trip data included date, starting and ending latitude and
longitude, starting and ending time, distance of trip (miles),
trip time (minutes), idling time (minutes), and counts of hard
braking, sudden acceleration, and speeding. The first 3 months
of a participant’s driving behavior were extracted and were
examined per 100 trips, where a trip was defined from “ignition
on” to “ignition off.” For example, an excursion from home to
the grocery store and back to home without any other stops
would be considered two trips. Hard braking, hard acceleration
and speeding events per trip were analyzed separately and in
combination. As multiple events of a particular type could occur
in a single trip, data were analyzed for each event type using a
two-step procedure: (a) number of trips per 100 in which such an
event occurred and (b) number of events per trip for trips with at
least one such event. In addition, other aspects of speeding, such
as the duration of speeding episodes, average speed in miles, trip
distance and trip time, were analyzed.

for a road test or driving cessation. DriveCam staff scored all
videos according to a standardized procedure developed and
validated by their company for commercial drivers (Myers et al.,
2012). DriveCam staff were blind to all clinical information
regarding dementia severity.
A commercial GPS datalogger (G2 Tracking DeviceTM , Azuga
Inc., San Jose, CA, United States) was plugged into the vehicle’s
OBD-II port and data collected every 30 s. This naturalistic
driving methodology, termed the Driving Real World InVehicle Evaluation System (DRIVES), is a validated method
of driving data collection for older adults (Babulal et al.,
2016). The device collected data every time the vehicle was
driven and recorded adverse driving events (hard braking,
sudden acceleration, and speeding) anytime they occurred during
a trip, regardless of the 30 s sampling that occurred for
other datalogger measures. Speeding was determined based on
the datalogger’s GPS, specifically the latitude and longitude
and the posted speed limit in the vehicle’s location. The
device compared the vehicle’s speed to the posted speed limit
and if the driver was going 6 miles per hour or more
above the posted speed limit in that area, an occurrence of
speeding was recorded.

Statistical Analysis

Driving Behavior

Participants with and without preclinical AD (all CDR = 0) were
matched on age and gender to participants with symptomatic
AD (CDR > 0). Spearman’s ρ correlational analyses using
Bonferroni correction for multiple comparisons were used to
examine relationships between driving behavior captured with
video and the GPS datalogger. Generalized linear modeling
(GLM) techniques were used to determine effects of amyloid and
cognitive status on event frequency per 1,000 miles driven. All
analyses were carried out using the GLM function in R 3.5.31 .
Event frequency was modeled via an over-dispersed Poisson
distribution with amyloid group (CN/A−, CN/A+, and AD) as
the sole model predictor. Exposure differences were accounted
for by adjusting for 1,000 miles driven via an offset variable.
Point and interval estimates of group effects were estimated in
the logarithmic scale as log (Rate Ratios) and then exponentiated.
In addition, measures of cognition (MMSE, Trails A and Trails B
time) were analyzed as secondary predictors of event frequency.

A total of 3 months of driving were selected for study for all
participants from a larger sample of longitudinal driving. Three
months were selected because the cognitively impaired group was
enrolled in a driving intervention trial where the first 3 months
were monitoring only. Inclusion of only the first 3 months of
driving avoids any confounds associated with the intervention.
To ensure that we were only analyzing the driving behavior of
the study driver, videos captured by other drivers were deleted.
Since the driver cannot be identified by the GPS logger, drivers
had to be driving their vehicle for at least 75% of the time to be
included in the current study. Vehicle use was reported by the
study partner (M = 94%, range = 75–100). The cognitively normal
control group were exclusive drivers of their vehicles (100%). For
all groups, any driving events were deleted if they were captured
during known times that the study driver was not driving due to
illness, travel, etc.
Driving errors captured by video were categorized into the
following behaviors and scored according to total demerit points:
collisions/near collisions, distractions (food, passengers, cell
phone, and other electronic devices), awareness (late response,
poor scanning of roadway, and failure to check mirrors), driver
conduct (poor judgment, aggressive/reckless), fundamentals
(excessive speed for conditions, failure to leave an out, and unsafe
lane change), following too close, driver condition (drowsy),
traffic violation (rolling stop, failure to stop at stop sign or light,
speeding, not on designated roadway, and unsafe/risky behavior).
The specific events or problems were graded for safety risk
on a 0–10 point demerit scale. A single unsafe driving event
could have more than one demerit category, such as judgment
error combined with poor awareness of intersection, leading to a
combined driving severity rating score for the individual items.
Error frequency was used to describe error types. Total demerit
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RESULTS
Demographic characteristics of these older drivers are presented
in Table 1. Groups were matched on age (p = 0.95), education
(p = 0.19), and gender. As expected, the early AD group had
lower MMSE scores than the cognitively normal groups. When
examining the early AD group with the video technology, there
were four collisions with objects such as curbs, mail boxes, parked
cars, but none with other moving vehicles. The most frequently
occurring safety events were driving unbelted, late response, too
fast for conditions, rolling stop, poor judgment, following too
close, speeding, and failing to scan intersections (see Figure 1).
1

4
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FIGURE 1 | Total number of unsafe driving events video recorded over 3 months of driving in the AD group (n = 11).

The next set of analyses included all three groups to examine
differences in driving behavior using the DRIVES. Table 2 shows
that hard braking events were the most commonly occurring
behavior on a per trip basis across all three groups, followed
by speeding in the CN/A− group and by hard acceleration
in the CN/A+ and early AD groups. Summing across event
types, driving events occurred in one in five trips taken by
CN/A− or early AD drivers vs. one in eight trips taken
by CN/A+. When only considering trips in which adverse
driving events occurred (see Table 3), repeat events in the
same trip were only common for speeding, with 0.9 more
speeding events per trip on average in the CN/A− and early
AD groups compared to the amyloid positive group (4.3 vs. 3.4
speeding events).
To control for driving exposure, driving events were corrected
per 1,000 miles driven (see Table 4 for point estimates and 95%
confidence intervals for the driving event rate per 1,000 miles
driven). After correcting for driving exposure, speeding was the
most common event type in both the CN/A− and early AD
groups, while hard braking remained the most common event
type in the CN/A+. Table 5 shows point estimates and 95%

TABLE 3 | Adverse driving event count per trip for trips including an event using
DRIVES technology.
Event type
CN/A−

Hard breaking

CN/A+

AD

11.07

8.13

8.52

Hard acceleration

5.98

4.45

8.52

Speeding

9.81

2.21

5.52

21.50

12.61

19.42

Overall
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AD

Hard breaking

1.27

1.26

1.28

Hard acceleration

1.47

1.26

1.41

Speeding

4.27

3.37

4.30

Overall

3.01

1.85

2.40

Event type

Group
CN/A−

CN/A+

AD

Hard breaking

19.7 (13.9, 27.8)

13.9 (10.1, 19.3)

18.1 (13.2, 25.0)

Hard acceleration

12.3 (3.5, 42.8)

7.6 (3.7, 15.7)

20.0 (8.0, 50.5)

Speeding

58.5 (37.7, 90.6)

10.1 (3.4, 30.4)

39.6 (18.3 86.0)

Overall

90.4 (69.0, 118.4)

31.6 (17.6, 57.0)

77.8 (50.3, 120.3)

confidence intervals for the ratio of driving events per 1,000
miles driven between (a) the cognitively normal groups (CN/A−
vs. CN/A+) and (b) early AD vs. preclinical AD (CN/A+).
The preclinical AD group had the lowest rate across all three
types of driving events (hard braking, hard acceleration, and
speeding), but the differences were especially pronounced for
speeding behavior.
Spearman correlations were calculated to examine the
relationship between error types captured with each technology
in the mild AD group. The strongest correlations were between

Group
CN/A−

CN/A+

TABLE 4 | Adverse driving rate per 1,000 miles driven (95% Confidence Interval)
using DRIVES technology.

TABLE 2 | Adverse driving event rate per 100 trips using DRIVES technology.
Event Type

Group
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correlated with lower speeding event rates with increasing Trails
A time (p = 0.03), whereas the later increase in events was
related to higher hard acceleration event rates with increasing
Trails A time (p = 0.09). Hard braking event rates were relatively
insensitive to Trails A time (p = 0.64).

TABLE 5 | Ratios of adverse driving rates per 1,000 miles driven (95% Confidence
Interval) using DRIVES technology.
Event type

Group
CH/Amyloid− vs. CH/Amyloid+

AD vs. CH/Amyloid+

Hard breaking

1.41 (0.88, 2.27)

1.30 (0.83, 2.05)

Hard acceleration

1.62 (0.38, 6.84)

2.64 (0.82, 8.53)

Speeding

5.78 (1.77, 18.90)++

3.92 (1.02, 15.10)+

Overall

2.86 (1.50, 5.46)+++

2.46 (1.18, 5.11)+

+ Implies

DISCUSSION
Two in-vehicle technologies were used in our study to
characterize driving errors and behaviors in older adult drivers
with preclinical and early symptomatic AD compared to
cognitively normal adults without any evidence of AD pathology.
In the early AD drivers, g-forced triggered events produced
common errors predominantly related to inadequate anticipation
of situations, such as late response or driving too fast for
the situation. AD drivers also frequently showed errors of
judgment and made frequent traffic violations around speeding
and responding to road signage (i.e., stop signs and traffic
lights). Despite these instances of poor judgment, actual
collisions were very rare during the study period. These g-force
triggered safety events are consistent with the types of driving
events we previously captured with continuous video recording
in mild AD drivers compared to cognitively normal older

p < 0.05, ++ Implies p < 0.01, +++ Implies p < 0.001.

speeding registered by the datalogger and collision/near collisions
and fundamentals of driving (i.e., failing to keep an out, too
fast for conditions, and failure to yield; rho = 0.81 and 0.87,
respectively. Hard breaking and hard acceleration were not
consistently related to errors captured by video analysis.
Poisson regression models showed no significant effect of
MMSE or Trails B time on driving event frequency (count of
braking, speeding, and sudden acceleration in a trip). However,
Trails A time had significant non-linear effects on overall event
frequency (p = 0.03) that are depicted graphically in Figure 2.
Further analysis of the non-linear effects (e.g., parabolic curve)
taken apart showed that the initial drop in driving events was

FIGURE 2 | Adverse driving rates per 1,000 miles driven using DRIVES technology as a function of Trail Making Part A duration (in seconds).
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This study utilized two different passive monitoring in-vehicle
technologies to understand driving behavior. As such, it was of
interest to explore the relationship between behaviors captured
with g-force triggered video technology vs. the data logger, as the
video provides more context to the behaviors captured with the
data logger. Data indicated that some, but not all, event types
were highly related. Specifically instances of speeding registered
by the datalogger were related to instances of collision/near
collisions and errors in driving fundamentals. Hard breaking
and hard acceleration were not strongly related to safety errors.
These relationships could only be examined in a small sample of
early AD participants, and more work will be needed to better
understand these findings, but preliminarily, these data support
the idea that aggressive events captured with the data logger may
indeed reflect risky driving behavior.
There are several limitations to this study. First, this is a
small sample of older drivers, and results should be viewed
as preliminary and only applicable to the aging population.
The CN and early AD participants were recruited from two
regionally different locations. It is possible that geographic
differences in population density, type of driving, and seasonal
weather changes may have impacted the results. The cognitively
normal older adult drivers (CDR 0) did not have the video
technology installed in their vehicles, so it is unclear how these
behaviors may occur in a cognitively normal population or the
degree to which amyloidosis might influence this relationship
based on these data alone. In addition, it is unclear the
degree to which events captured with the GPS data logger
correlate with actual unsafe behavior or simply more assertive or
effective defensive driving in a healthy population. The strong
relationship between video captured safety events and GPS
events in the cognitively impaired group would suggest that
the GPS captured events reflect actual risky behavior, possibly
more erratic driving, in the cognitively impaired group. Lastly,
results need be replicated in a larger sample of racially and
ethnically diverse older drivers as participants in this study were
all non-Hispanic white, which limits generalizability to other
diverse populations.
Our results offer preliminary findings that suggest that
in-vehicle technology can detect behavioral differences
between drivers at different points in the spectrum of
normal aging to early AD. With the increase in Advanced
Driver Assistance Systems (ADAS) as standard features
in vehicles, instrumented vehicle technology may offer a
unique opportunity to detect early behavioral change in older
adults that could signal increased risk for unsafe driving.
These types of technology could be used to identify when an
individual may need to start considering driving retirement
with instances of unsafe behaviors serving as early markers of
cognitive decline. Objective measurement of driving changes,
in conjunction with report of driving changes using driving
questionnaires could lead to further assessment with an
occupational therapist, driving specialist, or monitoring by a
healthcare provider. Future research should employ multiple
modalities for assessing driving behavior over extended
periods of time to obtain a more complete characterization of
the aging driver.

adults (Davis et al., 2012). These findings also confirm prior
data that used a semiautomated data reduction method to
isolate relevant driving errors from continuous video recorded
naturalistic driving to detect cognitive impairment-associated
driving behaviors in older adults (Davis et al., 2018; Moharrer
et al., 2020). This suggests that an event-based approach, rather
than more costly and staff time intensive continuous monitoring
of behavior via video, may be a sensitive method to study
driving risk in AD.
Global positioning system data logger technology was used
to address potential differences in driving behaviors among
cognitively normal, preclinical AD, and symptomatic AD. From
this data, a distinct pattern of driving behavior emerged among
drivers with preclinical AD compared to cognitively normal
older adults without evidence of AD and early AD. Specifically,
drivers with preclinical AD drove more slowly and had the lowest
number of aggressive events over the 3-month period. These data
are also consistent with prior work showing that older drivers
in the preclinical phase of AD restrict their driving compared to
healthy peers (Babulal et al., 2019; Roe et al., 2019).
The current results extend these findings by offering insights
into how driving may change across the spectrum of normal
aging to symptomatic AD by including a group of mild AD
drivers for comparison. Results suggest that in the earliest stage
of AD there may be a period of self-regulatory behavior during
amyloid accumulation but where cognitive functioning remains
unaffected. As the disease progresses and cognition begins
to decline with disease progression and neurodegeneration,
inhibitory control over more aggressive driving behavior may
begin to erode. As such, the AD drivers may revert back
to “normal” driving habits including excessive speed. This is
consistent with prior work showing that AD drivers whose
naturalistic driving was video recorded showed poorer tactical
self-regulation behavior and made twice as many critical events
as healthy older drivers. They were also three times more
likely to be unaware of these events (Paire-Ficout et al., 2018).
Unfortunately, the early AD group may need to continue to use
compensatory strategies (i.e., cautious driving) to prevent more
egregious safety errors and accidents. It is possible that early AD
drivers could maintain independence longer by increasing their
awareness of driving errors and the provision of compensatory
strategies. Prior intervention studies suggest that this may be
possible. For example, we showed that a behavioral intervention
aimed at correcting the specific driving errors reduced the
frequency of driving errors in a group of drivers with early AD
(Ott et al., 2017a).
Given that the cognitive processes of attention and executive
functioning decline in AD and have been shown to relate
to driving errors (Anderson et al., 2012; Papandonatos et al.,
2015), we examined the relationship between measures of
these constructs and driving events captured by the data
logger. In this study, simple psychomotor speed was associated
with driving behavior. Specifically, more acceleration events,
slower speeds, and more overall events were associated with
slower psychomotor speed. This suggests a relationship between
cognitive impairment and driving behaviors may be captured
with the data logger.
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